MYLK and myocardial infarction: This fact prompted us to study the effectiveness of a new MLCK inhibitor, PIK7 [17], in a model of myocardial infarction in rats to evaluate its microvascular hyperpermeability counteracting effect and its capacity to limit no-reflow conditions.